Emcure Pharmaceuticals rises on inking pact to acquire remaining 12.05% stake in Gennova
Emcure Pharmaceuticals is currently trading at Rs. 1799.95, up by 7.50 points or 0.42% from its previous closing of Rs. 1792.45 on the BSE.
The scrip opened at Rs. 1790.10 and has touched a high and low of Rs. 1839.90 and Rs. 1790.10 respectively. So far 3094 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1944.00 on 25-Jun-2026 and a 52 week low of Rs. 1260.10 on 30-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1,860.00 and Rs. 1783.60 respectively. The current market cap of the company is Rs. 34,151.91 crore.
The promoters holding in the company stood at 77.87%, while Institutions and Non-Institutions held 9.46% and 12.69% respectively.
Emcure Pharmaceuticals has inked pact to acquire remaining 12.05% stake in its subsidiary company -- Gennova Biopharmaceuticals (Gennova). The company has executed Share Transfer Agreements with all the individual shareholders of Gennova for acquisition of 663,865 equity shares Gennova. The company will acquire the stake for a consideration of Rs 231.87 crore payable in cash in one or more tranches.
After completion of the transaction, the Gennova will become a wholly-owned subsidiary of the company. Currently, the company owns 87.95% shareholding in Gennova. Gennova is involved in the business of research and development, manufacturing and marketing of biotechnology-based products.
